Human evidence record · Omberacetam (Noopept)
Noopept in mild cognitive impairment after stroke
MMSE and association tests improved relative to controls after two months.
Quick read
Human evidence record
What this study tells us
This was an early human study designed mainly to measure exposure, tolerability or a preliminary signal. Without stronger blinded controls, it should not be treated as definitive proof of benefit.
Who was studied?
Stroke patients with mild cognitive impairment
How many?
n=60
What happened?
MMSE and association tests improved relative to controls after two months.
What stops us overclaiming?
Open-label, older, single-country publication, unclear blinding/randomisation and not a healthy population.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
MMSE and association tests improved relative to controls after two months.
Study details
Study designOpen prospective clinical study
PhaseNot applicable
PopulationStroke patients with mild cognitive impairment
Sample size60
RouteOral
Regimen / exposure20 mg daily
Duration2 months reported treatment effect
ComparatorControl group in open study
Primary endpoint / questionCognitive test change
Safety resultAuthors described high safety.
Key limitationsOpen-label, older, single-country publication, unclear blinding/randomisation and not a healthy population.
Registry / identifierPMID 22500312